Charalambos Andreadis, MD
Hematology/Oncology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 4
- Since medical school
- 28 years
- Columbia University College of Physicians and Surgeons, 1998
Offices
4 locations · University of California San Francisco · UCSF Medical Group Business Services · Regents of the University of California
Hospitals listed: John Muir Medical Center - Walnut Creek Campus · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Andreadis’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- John Muir Medical Center - Walnut Creek CampusWalnut Creek, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 2.01 (1.17 to 2.85) · 2,206 cases, Jul 2022 – Jun 2024Worse than the national rate — Death rate among surgical inpatients with serious treatable complications: 222.42 (177.82 to 267.02) · 120 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.4 (0.91 to 1.9) · 9,764 cases, Jul 2022 – Jun 2024Worse than the national rate — SSI - Colon Surgery: 2.734, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.536, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.341, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.455, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.245, Oct 2024 – Sep 2025
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for John Muir Medical Center - Walnut Creek Campus
Behind the star rating — Deaths: 3 better, 2 the same, 2 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 3 better, 5 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 2.01 (1.17 to 2.85) · 2,206 cases | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 222.42 (177.82 to 267.02) · 120 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.4 (0.91 to 1.9) · 9,764 cases | Worse | Jul 2022 – Jun 2024 |
| SSI - Colon SurgeryInfections | 2.734 | Worse | Oct 2024 – Sep 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.536 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.341 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.455 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.245 | Better | Oct 2024 – Sep 2025 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.87 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 131 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 695 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.5 · 827 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.1 · 509 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 4,483 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.35 (0.18 to 0.53) · 11,630 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.05 to 0.39) · 11,793 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.69 to 4.96) · 3,268 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.37 (0 to 2.94) · 1,631 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.76 (1.43 to 4.09) · 3,066 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.12 (0.22 to 12.02) · 1,580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.43 (1.21 to 7.64) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 685 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 615 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.88 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 93 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 729 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.1 · 91 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13 · 736 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 34.8 · 842 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 818 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.4) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.2 to 15.5) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 584 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 139 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.9) · 222 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 321 cases | No different | Jan 2024 – Dec 2024 |
What patients said (758 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$77,466
Medicare paid this office $77,466 for 232 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 147 | $38,729 | $118 |
| Return visit (30+ min) | 88 | $8,607 | $73 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 191 | $5,411 | $14 |
| New patient visit (60+ min) | 26 | $3,692 | $142 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 16 | $1,136 | $67 |
See all 6 services
| Long return visit (40+ min) | 147 | $38,729 | $118 |
| Return visit (30+ min) | 88 | $8,607 | $73 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 191 | $5,411 | $14 |
| New patient visit (60+ min) | 26 | $3,692 | $142 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 16 | $1,136 | $67 |
| Insertion of needle into vein for collection of blood sample | 15 | $545 | $9 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy and aspiration of bone marrow sample for diagnosis | – | – | 14 | 16 | 11 | 17 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
232 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 6% · Women 45% · Also on Medicaid 17% · Health risk score 2.38. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 60% · Chronic kidney disease 25% · Coronary heart disease 24% · Depression 23% · Diabetes 22% · Atrial fibrillation 22% · Cancer 20% · Heart failure 18% · COPD 12% · Stroke 7% · Dementia 6%.
The office billed $675,475, Medicare allowed $105,116 and paid $77,466; for 3,355 services of 29 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 232 | 3,355 | 73 | 2.38 | $675,475 | $77,466 |
| 2023 | 249 | 1,791 | 72 | 2.52 | $731,867 | $88,669 |
| 2022 | 249 | 659 | 71 | 2.39 | $474,132 | $62,785 |
| 2021 | 219 | 996 | 72 | 2.76 | $522,753 | $61,326 |
| 2020 | 163 | 494 | 72 | 2.84 | $425,667 | $37,210 |
| 2019 | 174 | 462 | 71 | 3.00 | $440,418 | $43,382 |
| 2018 | 180 | 496 | 70 | 2.76 | $502,047 | $42,460 |
| 2017 | 198 | 583 | 69 | 3.07 | $558,816 | $46,868 |
| 2016 | 182 | 794 | 67 | 2.99 | $708,265 | $66,160 |
| 2015 | 169 | 702 | 67 | 2.97 | $662,776 | $58,261 |
| 2014 | 166 | 697 | 65 | 2.68 | $794,152 | $55,979 |
| 2013 | 137 | 699 | 63 | 2.58 | $726,995 | $51,817 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Long return visit (40+ min) | 138 | $36,937 | $121 |
| Return visit (30+ min) | 95 | $8,353 | $67 |
| New patient visit (60+ min) | 28 | $4,542 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $4,507 | $107 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 11 | $750 | $68 |
| Insertion of needle into vein for collection of blood sample | 22 | $487 | $8 |
2022: 6 services
| Long return visit (40+ min) | 142 | $36,786 | $123 |
| Return visit (30+ min) | 81 | $7,825 | $74 |
| New patient visit (60+ min) | 48 | $7,514 | $157 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $4,462 | $91 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 16 | $920 | $57 |
| Insertion of needle into vein for collection of blood sample | 17 | $106 | $3 |
2021: 5 services
| Long return visit (40+ min) | 119 | $32,301 | $121 |
| New patient visit (60+ min) | 48 | $7,734 | $161 |
| Return visit (30+ min) | 75 | $7,114 | $76 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $5,121 | $91 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 14 | $984 | $70 |
2020: 3 services
| Long return visit (40+ min) | 128 | $27,532 | $92 |
| New patient visit (60+ min) | 22 | $3,354 | $152 |
| Return visit (30+ min) | 36 | $2,378 | $61 |
2019: 4 services
| Long return visit (40+ min) | 133 | $31,081 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $4,662 | $93 |
| New patient visit (60+ min) | 31 | $4,652 | $150 |
| Return visit (30+ min) | 12 | $924 | $71 |
2018: 4 services
| Long return visit (40+ min) | 96 | $16,271 | $96 |
| Return visit (30+ min) | 91 | $9,306 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $8,801 | $93 |
| New patient visit (60+ min) | 17 | $2,533 | $149 |
2017: 6 services
| Long return visit (40+ min) | 60 | $12,336 | $90 |
| Return visit (30+ min) | 95 | $12,055 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $9,142 | $92 |
| New patient visit (60+ min) | 25 | $3,416 | $137 |
| Biopsy of bone marrow | 28 | $2,012 | $67 |
| Short return visit (20+ min) | 14 | $804 | $40 |
2016: 8 services
| Long return visit (40+ min) | 69 | $23,519 | $94 |
| Return visit (30+ min) | 93 | $13,460 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $13,281 | $92 |
| New patient visit (60+ min) | 16 | $2,282 | $143 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,921 | $64 |
| Biopsy of bone marrow | 18 | $1,560 | $68 |
| Short return visit (20+ min) | 19 | $1,192 | $43 |
| Hospital discharge day management, 30 minutes or less | 15 | $984 | $66 |
2015: 8 services
| Long return visit (40+ min) | 62 | $26,649 | $95 |
| Return visit (30+ min) | 70 | $11,055 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $7,457 | $92 |
| New patient visit (60+ min) | 14 | $2,097 | $150 |
| Short return visit (20+ min) | 27 | $1,834 | $44 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,499 | $65 |
| New patient visit (45+ min) | 13 | $1,395 | $107 |
| Biopsy of bone marrow | 17 | $1,256 | $66 |
2014: 7 services
| Long return visit (40+ min) | 61 | $18,968 | $97 |
| Return visit (30+ min) | 77 | $16,890 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $7,054 | $93 |
| New patient visit (60+ min) | 15 | $2,254 | $150 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,987 | $181 |
| Biopsy of bone marrow | 19 | $1,321 | $70 |
| Short return visit (20+ min) | 21 | $1,082 | $43 |
2013: 7 services
| Return visit (30+ min) | 75 | $19,253 | $64 |
| Long return visit (40+ min) | 41 | $11,134 | $91 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $8,306 | $90 |
| Mechanical separation of white blood cells and platelets from blood | 11 | $3,614 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $2,559 | $58 |
| Short return visit (20+ min) | 21 | $1,138 | $41 |
| Hospital discharge day management, 30 minutes or less | 12 | $784 | $60 |
Medicaid work
$16,761 in 2024
Medicaid paid $16,761 for 120 billed services this clinician did in 2024, up to 20 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 120 | $16,761 |
| 2024 | 120 | 1 | 20 | $16,761 |
| 2023 | 123 | 1 | 18 | $16,942 |
| 2022 | 187 | 3 | 21 | $18,971 |
| 2021 | 50 | 3 | 14 | $4,198 |
| 2020 | 37 | 1 | 22 | $2,524 |
| 2019 | 429 | 4 | 32 | $21,871 |
| 2018 | 283 | 7 | 22 | $4,389 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 123 | $16,942 |
2022
| Long return visit (40+ min) | 159 | $18,012 |
| COMPREHENSIVE METABOLIC PANEL | 14 | $677 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 14 | $282 |
2021
| COMPREHENSIVE METABOLIC PANEL | 17 | $1,773 |
| Long return visit (40+ min) | 15 | $1,754 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 18 | $671 |
2020
| Long return visit (40+ min) | 37 | $2,524 |
2019
| Long return visit (40+ min) | 188 | $16,700 |
| COMPREHENSIVE METABOLIC PANEL | 60 | $2,391 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 127 | $2,152 |
| Lactate dehydrogenase (LD), (LDH) | 54 | $628 |
2018
| Long return visit (40+ min) | 33 | $2,598 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 121 | $670 |
| Return visit (30+ min) | 12 | $533 |
| COMPREHENSIVE METABOLIC PANEL | 63 | $429 |
| Hospital outpatient clinic visit for assessment and management of a patient | 20 | $97 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 17 | $61 |
| Lactate dehydrogenase (LD), (LDH) | 17 | $0 |
Drugs they prescribed that Part D paid
$3,894,959
Pharmacies billed $3,894,959 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
463 generic and fewer than 11 brand-name prescriptions · $3,894,959 in drug cost · 53 antibiotic prescriptions to 18 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Calquence | 54 | $749,431 | $13,878 |
| Revlimid | 37 | $692,836 | $18,725 |
| Venclexta | 52 | $610,710 | $11,744 |
| Brukinsa | 35 | $506,681 | $14,477 |
| Imbruvica | 26 | $445,177 | $17,122 |
See all 17 drugs
| Calquence | None | 54 | $749,431 | $13,878 |
| Revlimid | None | 37 | $692,836 | $18,725 |
| Venclexta | None | 52 | $610,710 | $11,744 |
| Brukinsa | None | 35 | $506,681 | $14,477 |
| Imbruvica | None | 26 | $445,177 | $17,122 |
| Jaypirca | None | 19 | $400,936 | $21,102 |
| Lenalidomide | None | 18 | $253,983 | $14,110 |
| Gamunex-C | Immune globulin | 12 | $35,767 | $2,981 |
| Entecavir | None | 29 | $6,548 | $226 |
| Atovaquone | None | 18 | $4,450 | $247 |
| Acyclovir | None | 125 | $2,543 | $20 |
| Valacyclovir | None | 15 | $1,305 | $87 |
| Ondansetron | None | 30 | $351 | $12 |
| Sulfamethoxazole-Trimethoprim | None | 30 | $133 | $4 |
| Prednisone | None | 33 | $124 | $4 |
| Levofloxacin | None | 14 | $114 | $8 |
| Lorazepam | None | 18 | $64 | $4 |
Year by year
| 2024 | 733 | 96 | None | None | $3,894,959 |
| 2023 | 580 | 94 | None | None | $2,379,219 |
| 2022 | 579 | 101 | None | None | $1,514,189 |
| 2021 | 623 | 78 | None | 26% | $1,617,375 |
| 2020 | 685 | 78 | 2% (11) | 33% | $2,461,754 |
| 2019 | 616 | 64 | 3% (19) | 27% | $1,591,005 |
| 2018 | 597 | 80 | None | 32% | $1,865,295 |
| 2017 | 743 | 116 | 3% (21) | None | $1,536,319 |
| 2016 | 817 | 106 | 2% (18) | 21% | $1,200,901 |
| 2015 | 739 | 71 | None | None | $897,513 |
| 2014 | 670 | 70 | 4% (28) | 21% | $666,867 |
| 2013 | 657 | 57 | 2% (15) | 14% | $380,718 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Calquence | 47 | $743,722 | $15,824 |
| Revlimid | 20 | $387,270 | $19,363 |
| Imbruvica | 26 | $355,137 | $13,659 |
| Venclexta | 18 | $253,791 | $14,100 |
| Entecavir | 20 | $19,335 | $967 |
| Eliquis | 13 | $9,625 | $740 |
| Acyclovir | 110 | $2,899 | $26 |
| Valacyclovir | 14 | $1,540 | $110 |
| Gabapentin | 11 | $343 | $31 |
| Levothyroxine | 12 | $276 | $23 |
| Levofloxacin | 15 | $224 | $15 |
| Ondansetron | 22 | $169 | $8 |
| Prednisone | 22 | $112 | $5 |
| Sulfamethoxazole-Trimethoprim | 35 | $103 | $3 |
| Allopurinol | 12 | $55 | $5 |
| Lorazepam | 11 | $43 | $4 |
2022: 18 drugs
| Revlimid | None | 17 | $327,850 | $19,285 |
| Imbruvica | None | 26 | $318,687 | $12,257 |
| Calquence | None | 12 | $170,195 | $14,183 |
| Brukinsa | None | 13 | $163,729 | $12,595 |
| Gamunex-C | Immune globulin | 12 | $36,342 | $3,028 |
| Eliquis | None | 25 | $14,307 | $572 |
| Entecavir | None | 27 | $13,241 | $490 |
| Atovaquone | None | 13 | $11,238 | $864 |
| Acyclovir | None | 98 | $2,164 | $22 |
| Valacyclovir | None | 13 | $1,309 | $101 |
| Azithromycin | None | 14 | $360 | $26 |
| Ondansetron | None | 25 | $311 | $12 |
| Prednisone | None | 29 | $223 | $8 |
| Gabapentin | None | 15 | $208 | $14 |
| Prochlorperazine Maleate | None | 18 | $153 | $9 |
| Sulfamethoxazole-Trimethoprim | None | 27 | $92 | $3 |
| Lorazepam | None | 22 | $74 | $3 |
| Allopurinol | None | 13 | $59 | $5 |
2021: 17 drugs
| Revlimid | None | 39 | $677,808 | $17,380 |
| Imbruvica | None | 36 | $414,138 | $11,504 |
| Calquence | None | 13 | $187,372 | $14,413 |
| Gamunex-C | Immune globulin | 24 | $71,684 | $2,987 |
| Entecavir | None | 50 | $23,665 | $473 |
| Eliquis | None | 12 | $6,327 | $527 |
| Acyclovir | None | 106 | $2,646 | $25 |
| Valacyclovir | None | 16 | $978 | $61 |
| Fluconazole | None | 14 | $659 | $47 |
| Ondansetron | None | 29 | $567 | $20 |
| Azithromycin | None | 19 | $333 | $18 |
| Gabapentin | None | 26 | $276 | $11 |
| Prednisone | None | 28 | $263 | $9 |
| Levofloxacin | None | 17 | $163 | $10 |
| Sulfamethoxazole-Trimethoprim | None | 27 | $161 | $6 |
| Prochlorperazine Maleate | None | 13 | $125 | $10 |
| Allopurinol | None | 13 | $72 | $6 |
2020: 18 drugs
| Imbruvica | None | 85 | $1,106,549 | $13,018 |
| Revlimid | None | 50 | $848,433 | $16,969 |
| Calquence | None | 11 | $157,861 | $14,351 |
| Jakafi | None | 11 | $148,095 | $13,463 |
| Posaconazole | None | 14 | $45,814 | $3,272 |
| Gamunex-C | Immune globulin | 12 | $33,145 | $2,762 |
| Entecavir | None | 51 | $18,659 | $366 |
| Eliquis | None | 18 | $9,474 | $526 |
| Ursodiol | None | 11 | $4,974 | $452 |
| Fluconazole | None | 31 | $3,702 | $119 |
| Acyclovir | None | 89 | $2,226 | $25 |
| Dexamethasone | None | 18 | $1,779 | $99 |
| Valacyclovir | None | 11 | $951 | $86 |
| Azithromycin | None | 21 | $294 | $14 |
| Gabapentin | None | 17 | $266 | $16 |
| Levofloxacin | None | 15 | $252 | $17 |
| Prednisone | None | 17 | $82 | $5 |
| Sulfamethoxazole-Trimethoprim | None | 11 | $61 | $6 |
2019: 16 drugs
| Imbruvica | 65 | $755,892 | $11,629 |
| Calquence | 14 | $192,653 | $13,761 |
| Revlimid | 12 | $188,752 | $15,729 |
| Entecavir | 41 | $19,236 | $469 |
| Eliquis | 20 | $9,107 | $455 |
| Fluconazole | 33 | $3,999 | $121 |
| Acyclovir | 66 | $1,434 | $22 |
| Azithromycin | 19 | $748 | $39 |
| Dexamethasone | 14 | $315 | $22 |
| Gabapentin | 15 | $245 | $16 |
| Ondansetron | 15 | $211 | $14 |
| Sulfamethoxazole-Trimethoprim | 40 | $172 | $4 |
| Prednisone | 20 | $160 | $8 |
| Prochlorperazine Maleate | 14 | $140 | $10 |
| Lorazepam | 21 | $111 | $5 |
| Allopurinol | 18 | $106 | $6 |
2018: 13 drugs
| Imbruvica | 84 | $941,159 | $11,204 |
| Revlimid | 29 | $441,766 | $15,233 |
| Venclexta | 17 | $192,222 | $11,307 |
| Noxafil | 14 | $82,890 | $5,921 |
| Entecavir | 30 | $23,960 | $799 |
| Enoxaparin | 13 | $2,179 | $168 |
| Acyclovir | 79 | $1,283 | $16 |
| Azithromycin | 20 | $812 | $41 |
| Valacyclovir | 13 | $374 | $29 |
| Prednisone | 32 | $245 | $8 |
| Gabapentin | 11 | $183 | $17 |
| Sulfamethoxazole-Trimethoprim | 36 | $91 | $3 |
| Lorazepam | 11 | $63 | $6 |
2017: 16 drugs
| Imbruvica | 79 | $878,583 | $11,121 |
| Revlimid | 15 | $229,090 | $15,273 |
| Venclexta | 13 | $132,869 | $10,221 |
| Entecavir | 37 | $30,307 | $819 |
| Xarelto | 18 | $7,301 | $406 |
| Eliquis | 11 | $5,195 | $472 |
| Acyclovir | 93 | $1,174 | $13 |
| Hydroxyurea | 29 | $756 | $26 |
| Fluconazole | 14 | $340 | $24 |
| Ondansetron | 14 | $266 | $19 |
| Prednisone | 37 | $236 | $6 |
| Omeprazole | 12 | $218 | $18 |
| Gabapentin | 13 | $155 | $12 |
| Sulfamethoxazole-Trimethoprim | 36 | $110 | $3 |
| Lorazepam | 28 | $77 | $3 |
| Levofloxacin | 16 | $74 | $5 |
2016: 20 drugs
| Imbruvica | 81 | $832,761 | $10,281 |
| Revlimid | 13 | $150,878 | $11,606 |
| Noxafil | 23 | $120,595 | $5,243 |
| Entecavir | 42 | $31,576 | $752 |
| Acyclovir | 132 | $1,674 | $13 |
| Methotrexate | 16 | $1,284 | $80 |
| Tacrolimus | 16 | $1,144 | $72 |
| Mercaptopurine | 17 | $1,011 | $59 |
| Fluconazole | 16 | $919 | $57 |
| Azithromycin | 28 | $609 | $22 |
| Dapsone | 12 | $551 | $46 |
| Gabapentin | 30 | $434 | $14 |
| Levofloxacin | 18 | $286 | $16 |
| Ondansetron | 17 | $278 | $16 |
| Prednisone | 29 | $258 | $9 |
| Lansoprazole | 12 | $186 | $15 |
| Metoprolol | 27 | $170 | $6 |
| Sulfamethoxazole-Trimethoprim | 20 | $112 | $6 |
| Atorvastatin | 11 | $101 | $9 |
| Lorazepam | 26 | $90 | $3 |
2015: 21 drugs
| Imbruvica | 51 | $475,642 | $9,326 |
| Revlimid | 17 | $134,094 | $7,888 |
| Enoxaparin | 25 | $21,489 | $860 |
| Entecavir | 24 | $20,448 | $852 |
| Ursodiol | 12 | $3,434 | $286 |
| Fluconazole | 33 | $3,172 | $96 |
| Qvar | 11 | $2,057 | $187 |
| Acyclovir | 97 | $1,309 | $13 |
| Mercaptopurine | 12 | $1,069 | $89 |
| Omeprazole | 27 | $496 | $18 |
| Dapsone | 14 | $479 | $34 |
| Azithromycin | 23 | $473 | $21 |
| Ondansetron | 15 | $432 | $29 |
| Prednisone | 34 | $354 | $10 |
| Atorvastatin | 36 | $236 | $7 |
| Gabapentin | 15 | $235 | $16 |
| Lorazepam | 28 | $195 | $7 |
| Montelukast | 16 | $191 | $12 |
| Levofloxacin | 12 | $177 | $15 |
| Sulfamethoxazole-Trimethoprim | 27 | $133 | $5 |
| Glipizide | 12 | $45 | $4 |
2014: 20 drugs
| Imbruvica | 27 | $257,591 | $9,540 |
| Revlimid | 25 | $189,776 | $7,591 |
| Enoxaparin | 14 | $32,817 | $2,344 |
| Baraclude | 18 | $21,506 | $1,195 |
| Ursodiol | 13 | $3,820 | $294 |
| Fluconazole | 19 | $2,212 | $116 |
| Acyclovir | 78 | $1,220 | $16 |
| Levofloxacin | 25 | $960 | $38 |
| Azithromycin | 23 | $832 | $36 |
| Dapsone | 13 | $697 | $54 |
| Omeprazole | 30 | $691 | $23 |
| Gabapentin | 26 | $424 | $16 |
| Atorvastatin | 33 | $318 | $10 |
| Ondansetron | 13 | $280 | $22 |
| Hydrocodone-Acetaminophen | 20 | $269 | $13 |
| Sulfamethoxazole-Trimethoprim | 19 | $229 | $12 |
| Zolpidem | 18 | $178 | $10 |
| Prednisone | 12 | $130 | $11 |
| Lorazepam | 20 | $81 | $4 |
| Allopurinol | 13 | $59 | $5 |
2013: 15 drugs
| Revlimid | 18 | $182,505 | $10,139 |
| Enoxaparin | 17 | $38,745 | $2,279 |
| Baraclude | 15 | $15,501 | $1,033 |
| Acyclovir | 98 | $1,861 | $19 |
| Fluconazole | 25 | $1,467 | $59 |
| Valacyclovir | 14 | $1,026 | $73 |
| Omeprazole | 37 | $818 | $22 |
| Gabapentin | 37 | $645 | $17 |
| Sulfamethoxazole-Trimethoprim | 37 | $367 | $10 |
| Atorvastatin | 15 | $288 | $19 |
| Levofloxacin | 18 | $272 | $15 |
| Lorazepam | 31 | $143 | $5 |
| Allopurinol | 20 | $96 | $5 |
| Amlodipine Besylate | 14 | $93 | $7 |
| Zolpidem | 11 | $71 | $6 |
Money from drug and device companies
$18,943 in 2025
| 2025 | 7 | 21 | $17,201 | $18,943 |
| 2024 | 4 | 19 | $14,555 | $15,973 |
| 2023 | 7 | 12 | $3,690 | $4,423 |
| 2022 | 7 | 16 | $10,686 | $11,521 |
| 2021 | 5 | 7 | $4,425 | $4,523 |
| 2020 | 2 | 3 | $10,695 | $10,695 |
| 2019 | 4 | 28 | $13,640 | $19,640 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | None | $11,599 | 4 payments
|
| Genmab U.S. | Epkinly | $3,651 | 4 payments
|
| Incyte | None | $2,055 | 1 payment
|
| Celgene | None | $927 | 6 payments
|
| Abbvie | Epkinly | $578 | 4 payments
|
| Genentech | Columvi | $102 | 1 payment
|
See all 21 published payments
| Genmab U.S. | Meals · 2025-12-06 | Epkinly | $122 |
| Abbvie | Meals · 2025-12-05 | Epkinly | $149 |
| Genmab U.S. | Meals · 2025-11-08 | Epkinly | $41 |
| Genmab U.S. | Meals · 2025-11-08 | Epkinly | $102 |
| Genmab U.S. | Consulting · 2025-11-08 | Epkinly | $3,386 |
| Kite Pharma | Meals · 2025-10-16 | Yescarta | $31 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-29 | None | $48 |
| E.R. Squibb & Sons L.L.C. | Travel · 2025-08-29 | None | $91 |
| Abbvie | Meals · 2025-08-27 | Epkinly | $108 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-08-18 | None | $9,073 |
| Celgene | Meals · 2025-08-06 | None | $65 |
| Celgene | Meals · 2025-08-06 | None | $28 |
| Celgene | Meals · 2025-08-06 | None | $30 |
| Celgene | Meals · 2025-08-06 | None | $50 |
| Celgene | Travel · 2025-08-06 | None | $462 |
| Celgene | Travel · 2025-08-05 | None | $293 |
| Abbvie | Consulting · 2025-07-14 | Epkinly | $300 |
| Genentech | Meals · 2025-06-20 | Columvi | $102 |
| Incyte | Consulting · 2025-05-29 | None | $2,055 |
| E.R. Squibb & Sons L.L.C. | Consulting · 2025-03-05 | None | $2,388 |
| Abbvie | Meals · 2025-01-30 | Imbruvica | $21 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $15,973
| E.R. Squibb & Sons L.L.C. | None | $5,730 | 2 payments
|
| Genmab U.S. | Epkinly | $4,289 | 11 payments
|
| Kite Pharma | Yescarta | $3,700 | 1 payment
|
| Abbvie | Imbruvica | $2,255 | 5 payments
|
2023: $4,423
| E.R. Squibb & Sons L.L.C. | None | $3,691 | 2 payments
|
| Seagen | None | $322 | 2 payments
|
| Genmab U.S. | Epkinly | $137 | 1 payment
|
| AbbVie | Epkinly | $130 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $65 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $47 | 2 payments
|
| Genentech USA | Lunsumio | $32 | 1 payment
|
2022: $11,521
| Kite Pharma | Tecartus | $5,000 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $2,212 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $1,980 | 2 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $1,650 | 2 payments
|
| Seagen | None | $409 | 4 payments
|
| Celgene | None | $222 | 4 payments
|
| Abbvie | Venclexta | $48 | 1 payment
|
2021: $4,523
| Kite Pharma | Tecartus | $2,250 | 1 payment
|
| Epizyme | Tazverik | $2,175 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $40 | 3 payments
|
| Celgene | None | $31 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $27 | 1 payment
|
2020: $10,695
| Incyte | None | $7,995 | 2 payments
|
| Kite Pharma | Yescarta | $2,700 | 1 payment
|
2019: $19,640
| Gilead Sciences | None | $12,781 | 8 payments
|
| Jazz Pharmaceuticals | None | $5,663 | 9 payments
|
| Novartis Pharmaceuticals | Kymriah | $1,136 | 10 payments
|
| Kite Pharma | None | $60 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Celgene Corporation · A Study To Compare the Efficacy and Safety of Jcar017 To Standard of Care in Adult Subjects With High-Risk, Transplant-Eligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (Transform) (Jcar017-Bcm-003) · 2019 | Their institution | $494,050 |
| Genmab U.S., Inc. · A Phase 1/2, Open-Label Safety Trial of Gen3013 in Patients With Relapsed, Progressive Or Refractory B-Cell Lymphoma. · 2023 | Their institution | $344,158 |
| Merck Sharp & Dohme Corporation · A Phase 1,Phase 2 Clinical Study To Evaluate the Safety and Efficacy of A Combination of Mk-4280 and Pembrolizumab Mk-3475 in Participants With Hematologic Malignancies · 2021 | Their institution | $322,940 |
| Genmab U.S., Inc. · A Phase 1/2, Open-Label Safety Trial of Gen3013 in Patients With Relapsed, Progressive Or Refractory B-Cell Lymphoma. · 2024 | Their institution | $314,001 |
| Hoffmann-La Roche Limited · Phase 1b Study of Each Glofitammab and Mosunetuzumab in Combination With M Cc20 and M Cc82 in Nhl · 2025 | Their institution | $283,683 |
| Celgene Corporation · A Study To Compare the Efficacy and Safety of Jcar017 To Standard of Care in Adult Subjects With High-Risk, Transplant-Eligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (Transform) · 2022 | Their institution | $263,497 |
| Celgene Corporation · Expanded Access Protocol (Eap) of Patients Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release (Jcar017-Nhl-001) · 2019 | Their institution | $227,178 |
| Celgene Corporation · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Transcend-Nhl-001) (17001) · 2019 | Their institution | $209,001 |
| Celgene Corporation · A Study To Compare the Efficacy and Safety of Jcar017 To Standard of Care in Adult Subjects With High-Risk, Transplant-Eligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (Transform) · 2020 | Their institution | $196,709 |
| Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2020 | Their institution | $196,253 |
| Merck Sharp & Dohme Corporation · A Phase 1,Phase 2 Clinical Study To Evaluate the Safety and Efficacy of A Combination of Mk-4280 and Pembrolizumab Mk-3475 in Participants With Hematologic Malignancies · 2020 | Their institution | $188,469 |
| Genentech, Inc. · Phase 1 Eih Cd19 4 1bbl · 2025 | Their institution | $171,618 |
| E.R. Squibb & Sons, L.L.C. · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Nhl) · 2024 | Their institution | $162,391 |
| Genentech, Inc. · Phase 1 Eih Cd19 4 1bbl · 2023 | Their institution | $158,247 |
| Hoffmann-La Roche Limited · Phase 1b Study of Each Glofitammab and Mosunetuzumab in Combination With M Cc20 and M Cc82 in Nhl · 2024 | Their institution | $155,075 |
| Novartis Pharmaceuticals Corporation · Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (Belinda) · 2020 | Their institution | $152,563 |
| Lilly USA, LLC · A Multicenter Phase 2 Study of Glofitamab With Pirtobrutinib for Relapsed Or Refractory Mantle Cell Lymphoma · 2024 | Their institution | $144,214 |
| Genentech, Inc. · Glofit Pirto in Nhl · 2025 | Their institution | $121,682 |
| Celgene Corporation · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Transcend-Nhl-001) · 2020 | Their institution | $120,277 |
| Genmab A/S · A Phase 1b/2, Open-Label Trial To Assess the Safety and Preliminary Efficacy of Epcoritamab (Gen3013; Duobody-Cd3xcd20) in Combination With Other Agents in Subjects With B-Cell Non-Hodgkin Lymphoma. · 2025 | Their institution | $119,074 |
| Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2023 | Their institution | $111,334 |
| Hoffmann-La Roche Limited · Phase 1b Study of Each Glofitammab and Mosunetuzumab in Combination With M Cc20 and M Cc82 in Nhl · 2023 | Their institution | $103,357 |
| Pharmacyclics LLC, an AbbVie Company · A Randomized Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma of the Activated-B-Cell Subtype · 2022 | Their institution | $100,000 |
| Pharmacyclics LLC, An AbbVie Company · Imbruvica · 2020 | Their institution | $100,000 |
| Pharmacyclics LLC, an AbbVie Company · A051301: A Randomized Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma of the Activated-B-Cell Subtype · 2021 | Their institution | $100,000 |
| Pharmacyclics LLC, an AbbVie Company · A Randomized Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma of the Activated-B-Cell Subtype · 2023 | Their institution | $100,000 |
| Merck Sharp & Dohme LLC · A Phase 1,Phase 2 Clinical Study To Evaluate the Safety and Efficacy of A Combination of Mk-4280 and Pembrolizumab Mk-3475 in Participants With Hematologic Malignancies · 2022 | Their institution | $89,013 |
| Novartis Pharmaceuticals Corporation · Phase II Diffuse Large B Cell Lymphoma Dlbcl · 2019 | Their institution | $88,087 |
| Celgene Corporation · A Phase I, Open-Label, Dose Finding Study of Cc-90002, A Monoclonal Antibody Directed Against Cd47, in Subjects With Advanced Solid and Hematologic Cancers · 2020 | Their institution | $79,164 |
| Amgen Inc. · [Nccn] A Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed Or Refractory Non-Hodgkin Lymphoma · 2019 | Their institution | $74,285 |
| Celgene Corporation · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Transcend-Nhl-001) · 2022 | Their institution | $72,072 |
| Genmab A/S · A Phase 1b/2, Open-Label Trial To Assess the Safety and Preliminary Efficacy of Epcoritamab (Gen3013; Duobody-Cd3xcd20) in Combination With Other Agents in Subjects With B-Cell Non-Hodgkin Lymphoma. · 2023 | Their institution | $71,550 |
| Novartis Pharmaceuticals Corporation · Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (Belinda) · 2021 | Their institution | $71,458 |
| Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2019 | Their institution | $70,804 |
| Celgene Corporation · A Phase I, Open-Label, Dose Finding Study of Cc-90002, A Monoclonal Antibody Directed Against Cd47, in Subjects With Advanced Solid and Hematologic Cancers · 2021 | Their institution | $56,008 |
| Merck Sharp & Dohme Corporation · A Phase 1,Phase 2 Clinical Study To Evaluate the Safety and Efficacy of A Combination of Mk-4280 and Pembrolizumab Mk-3475 in Participants With Hematologic Malignancies · 2019 | Their institution | $55,088 |
| Celgene Corporation · A Global Randomized Multicenter Phase 3 Trial of J · 2021 | Their institution | $52,391 |
| Celgene Corporation · Transcend 3l+ Cll- 17004 (Ph 1/2) - An Open-Label, Phase 1/2 Study of Jcar017 in Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) · 2023 | Their institution | $46,769 |
| Genmab A/S · A Phase 1b/2, Open-Label Trial To Assess the Safety and Preliminary Efficacy of Epcoritamab (Gen3013; Duobody-Cd3xcd20) in Combination With Other Agents in Subjects With B-Cell Non-Hodgkin Lymphoma. · 2024 | Their institution | $44,800 |
| Celgene Corporation · Long-Term Follow-Up Protocol for Participants Treated With Gene-Modified T Cells. A Prospective Study for the Long-Term Follow-Up (Ltfu) of Safety and Efficacy for All Pediatric and Adult Participants Exposed To Gene-Modified (Gm) T-Cell Therapy Participating in A Previous Celgene Sponsored Or Celgene Alliance Partner Sponsored Study. · 2025 | Their institution | $43,177 |
| Novartis Pharmaceuticals Corporation · Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (Belinda) · 2022 | Their institution | $42,208 |
| Genentech, Inc. · Phase 1 Eih Cd19 4 1bbl · 2024 | Their institution | $40,584 |
| Celgene Corporation · Transcend 3l+ Cll- 17004 (Ph 1/2) - An Open-Label, Phase 1/2 Study of Jcar017 in Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) · 2024 | Their institution | $36,421 |
| Novartis Pharmaceuticals Corporation · Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (Belinda) · 2019 | Their institution | $32,674 |
| E.R. Squibb & Sons, L.L.C. · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Nhl) · 2025 | Their institution | $31,516 |
| Novartis Pharmaceuticals Corporation · Phase II Diffuse Large B Cell Lymphoma Dlbcl · 2023 | Their institution | $30,839 |
| Celgene Corporation · Long-Term Follow-Up Protocol for Participants Treated With Gene-Modified T Cells · 2023 | Their institution | $29,899 |
| Celgene Corporation · Long-Term Follow-Up Protocol for Participants Treated With Gene-Modified T Cells · 2024 | Their institution | $29,407 |
| Celgene Corporation · Transform 2l Te Lbcl Bcm-003 - A Global Randomized Multicenter Phase 3 Trial of Jcar017 Compared To Standard of Care in Adult Subjects With High-Risk, Second-Line, Transplant-Eligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (Transfo · 2023 | Their institution | $29,063 |
| Celgene Corporation · (Jcar017-Eap-001) Expanded Access (Out of Spec) - Expanded Access Protocol (Eap) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release · 2023 | Their institution | $28,826 |
| Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2022 | Their institution | $28,301 |
| Novartis Pharmaceuticals Corporation · Phase II Diffuse Large B Cell Lymphoma Dlbcl · 2021 | Their institution | $27,885 |
| Novartis Pharmaceuticals Corporation · Phase II Diffuse Large B Cell Lymphoma Dlbcl · 2022 | Their institution | $25,576 |
| Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2024 | Their institution | $24,434 |
| Celgene Corporation · Long-Term Follow-Up Protocol for Subjects Treated · 2022 | Their institution | $24,387 |
| Genmab U.S., Inc. · A Phase 1/2, Open-Label Safety Trial of Gen3013 in Patients With Relapsed, Progressive Or Refractory B-Cell Lymphoma. · 2025 | Their institution | $24,128 |
| Celgene Corporation · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Nhl) · 2025 | Their institution | $22,877 |
| Novartis Pharmaceuticals Corporation · Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (Belinda) · 2023 | Their institution | $20,179 |
| Novartis Pharmaceuticals Corporation · A Phase II Study of Intensive Consolidation and Stem Cell Mobilization Therapy With Ofatumumab Etoposide and High Dose Arac Ova Followed By Autologous Stem Cell Transplantation in High Risk Patients With Relapsed and Or Refractory Diffuse Large Bcell Lymp · 2019 | Their institution | $18,976 |
| Celgene Corporation · A Study To Compare the Efficacy and Safety Ofjcar017to Standard of Care in Adult Subjects With High-Risk, Transplant-Eligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (Transform) · 2024 | Their institution | $18,218 |
| Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2024 | Their institution | $15,361 |
| Celgene Corporation · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Transcend-Nhl-001) · 2023 | Their institution | $13,797 |
| Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2023 | Their institution | $10,989 |
| Novartis Pharmaceuticals Corporation · Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (Belinda) · 2024 | Their institution | $10,305 |
| Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2021 | Their institution | $9,371 |
| Celgene Corporation · Expanded Access Protocol (Eap) for Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming for Commercial Release · 2024 | Their institution | $9,231 |
| Celgene Corporation · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Transcend-Nhl-001) · 2024 | Their institution | $9,198 |
| Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2021 | Their institution | $8,512 |
| Celgene Corporation · (Jcar017-Eap-001) Expanded Access (Out of Spec) (Bms Study Number: Ca082-P27) - Expanded Access Protocol (Eap) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release · 2022 | Their institution | $5,171 |
| Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2019 | Their institution | $4,256 |
| Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2020 | Their institution | $4,256 |
| Novartis Pharmaceuticals Corporation · Phase II Diffuse Large B Cell Lymphoma Dlbcl · 2020 | Their institution | $2,453 |
| Celgene Corporation · Expanded Access Protocol (Eap) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release · 2025 | Their institution | $2,110 |
| Novartis Pharmaceuticals Corporation · Long Term Follow Up of Patients Exposed To Lentiviral Based Cd19 Directed Car T Cell Therapy · 2025 | Their institution | $1,851 |
| Celgene Corporation · (Jcar017-Eap-001) Expanded Access (Out of Spec) (Bms Study Number: Ca082-P27) · 2021 | Their institution | $1,500 |
| Karyopharm Therapeutics Inc. · A Phase 2b Open-Label Study of Selinexor (Kpt 330) in Patients With Relapsed Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) · 2022 | Their institution | $1,475 |
| Celgene Corporation · A Study Related To Non-Hodgkin Lymphoma, Compares the Efficacy of Obinutizumab in Combination With Chemotherapy Versus Rituximab- Based Treatments for Untreated Advanced Cases (Cl-Nhl-13648) · 2019 | This clinician | $1,411 |
| Celgene Corporation · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Transcend-Nhl-001) · 2021 | Their institution | $1,145 |
| Celgene Corporation · An Open-Label, Phase 1/2 Study of Jcar017 in Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) (17004) · 2019 | This clinician | $1,144 |
| F. Hoffmann-La Roche AG · Phase 1b Study of Each Glofitammab and Mosunetuzumab in Combination With M Cc20 and M Cc82 in Nhl · 2025 | This clinician | $1,038 |
| E.R. Squibb & Sons, L.L.C. · An Open-Label, Phase 1/2 Study of Jcar017 in Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) · 2025 | Their institution | $937 |
| Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2025 | Their institution | $757 |
| Novartis Pharmaceuticals Corporation · Cctl019e2202 · 2023 | This clinician | $638 |
| Celgene Corporation · A Phase I, Open-Label, Dose Finding Study of Cc-90002, A Monoclonal Antibody Directed Against Cd47, in Subjects With Advanced Solid and Hematologic Cancers (Cc-90002-St-001) · 2019 | This clinician | $476 |
| Novartis Pharmaceuticals Corporation · A Phase II Single Arm Multicenter Open Label Trial To Determine the Efficacy and Safety of Ctl019 in Adult Patients With Refractory Or Relapsed Follicular Lymphoma · 2021 | This clinician | $355 |
| Novartis Pharmaceuticals Corporation · Cctl019e2202 · 2024 | This clinician | $349 |
| E.R. Squibb & Sons, L.L.C. · Expanded Access Protocol (Eap) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release · 2025 | Their institution | $267 |
| NOVARTIS PHARMACEUTICALS CORPORATION · Research Related Publications Support · 2019 | This clinician | $224 |
| Merck Sharp & Dohme LLC · A Phase 1,Phase 2 Clinical Study To Evaluate the Safety and Efficacy of A Combination of Mk-4280 and Pembrolizumab Mk-3475 in Participants With Hematologic Malignancies · 2023 | Their institution | $223 |
| Novartis Pharmaceuticals Corporation · Research Publication/ Writing Support · 2025 | This clinician | $115 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1205877669
- Licence
- PA MD073649L
- Trained
- Columbia University College of Physicians and Surgeons, 1998 · 28 years ago
- Group
- University of California San Francisco · UCSF Medical Group Business Services · Regents of the University of California
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- PA 1010419220001
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 3400 Spruce St, 15 Penn Tower, Philadelphia, PA, 19104
- NPI first listed
- 2006-06-09
- NPI last updated
- 2011-01-21
This is when the NPI record was last certified, not a medical board exam.